y16

Y16 is a G protein-coupled Rho GEFs inhibitor that synergizes with Rhosin/G04 to inhibit LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling. Y16 is also a specific inhibitor of LARG with a Kd of 76 nM.

Y16 acetate(429653-73-6 free base) is a G-protein–coupled Rho GEFs inhibitor; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.

Y16526 is a potent inhibitor of the CBP/p300 bromodomain (CBP/p300bromodomain) with an IC50 of 0.03 μM. Y16524 shows potential for research in acute myeloid leukemia (AML).

Y16524 is a potent inhibitor of the CBP/p300 bromodomain (CBP/p300bromodomain) with an IC50 value of 0.01 μM. It shows potential for research in acute myeloid leukemia (AML).

WNY1613 is a potent and selective PI3Kδ inhibitor with a piperazinone-containing purine scaffold, exhibiting anti-NHL effects both in vitro and in vivo by inhibiting phosphorylation of downstream components of PI3K in NHL cell lines and inducing apoptosis in cancer cells.

(Rac)-WAY-161503 is a selective and high-affinity agonist of the 5-HT2C receptor [Ki: 4 nM; EC50: 12 nM], exhibiting anti-obesity and antidepressant effects.

(Z)-3,11-dimethy-7-methylene-9,14-epoxy-1,6,10-dodecatrien-3-ol is a useful organic compound for research related to life sciences and the catalog number is T125942.

15-Hydroxy-16-kauren-19-oic acid is a useful organic compound for research related to life sciences and the catalog number is T131456.

WAY 163909 is an effective and selective agonist of the 5-HT(2C) receptor (Ki: 10.5±1.1 nM).

WAY 163909 hydrochloride is an effective agonist for the serotonin 5-HT2C receptor, with an EC50 value of 8 nM and a maximal efficacy of 90%. It shows minimal activity at the 5-HT2A receptor. The compound displays its selectivity with a Ki value of 10.5 nM at the 5-HT2C receptor, compared to higher Ki values at 5-HT2A (212 nM), 5-HT7 (343 nM), and 5-HT2B (485 nM) receptors, and it lacks significant activity at various other receptors.

WAY-166818 (WAY-818) is a synthetic nonsteroidal estrogen that acts as a selective agonist for ERβ.

The compound is a mechanism-based inhibitor of cytochrome P450 ω-hydroxylase.

WAY 161503 hydrochloride is a 5-HT2C receptor agonist.

EM 5519 is an antitumor antibiotic.

Binimetinib (ARRY-162) is a MEK1/2 inhibitor (IC50=12 nM) with selective and oral activity. Binimetinib has antitumor activity for the treatment of metastatic melanoma that cannot be resected or has a BRAF V600E or V600K mutation.

LY 163443 is an dual receptor antagonist of LTD4 and LTE4.

LY 164929 is a highly selective ligand for the lower affinity [3H]D-Ala2-D-Leu-5-enkephalin binding site.

LY-165163 is a selective antagonists of 5-HT1A and 5-HT1D serotonin receptor.

AL-3138 is a prostaglandin F2alpha (PGF2alpha) analogue which antagonizes FP prostanoid receptor-mediated inositol phosphates generation.

LY 163252 is a bio-active chemical.

LY 164846 is a novel oral cephalosporin that is effective against Staphylococcus, Streptococcus, Haemophilus influenzae, Catabella and Neisseria.

Safracin A is an antibiotic produced by Pseudomonas fluorescens A2-2.

3-(β-D-Glucopyranosyloxy)-1,6-dihydroxy-2-methyl-9,10-anthracenedione, also known as an anthraquinone, has been specifically extracted from [Rubia cordifolia].

MHY-1685 is a mammalian target of rapamycin (mTOR) inhibitor and a senescence inhibitor that can rejuvenate senile hCSCs by modulating autophagy.